thybetador (CS060380) / Cascade Pharma - LARVOL DELTA

Efficacy and Safety of CS060380, a Potent THR-β Agonist, in MASH: A Phase 2a Randomized Trial (OBESITY WEEK 2026) - No abstract available

Clinical • P2a data • Metabolic Dysfunction-Associated Steatohepatitis

A Study of CS060380 Tablets in Patients With MASH and Obesity (clinicaltrials.gov) - P2 | N=130 | Active, not recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Thybetador, a potent and selective THR-β agonist: results from a phase 1 first-in-human study in healthy volunteers and participants with elevated LDL-C (EASL 2026) - "Background and aims: Thybetador (CS060380) is a novel thyroid hormone receptor-beta (THR-β) agonist... In this Phase I trial, Thybetador exhibited a favorable safety profile and PK characteristics in both SAD and MAD studies. Robust PD effects were observed in the MAD study. Based on these findings, Phase II investigations are currently ongoing."

Clinical • First-in-human • Late-breaking abstract • P1 data • Dyslipidemia • APOB

A Study of CS060380 Tablets in Patients With MASH and Obesity (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

A Study of CS060380 Tablets in Patients With MASH and Obesity (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Cascade Pharmaceuticals, Inc

New P2 trial • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | N=60 ➔ 120 | Trial completion date: May 2026 ➔ Nov 2026 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Enrollment change • Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Cascade Pharmaceuticals, Inc

New P2 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: Cascade Pharmaceuticals, Inc | Active, not recruiting ➔ Completed

Trial completion • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Dysfunction-Associated Steatohepatitis